Detalhe da pesquisa
1.
Genome-wide detection of tandem DNA repeats that are expanded in autism.
Nature
; 586(7827): 80-86, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32717741
2.
Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma.
Blood
; 137(11): 1478-1490, 2021 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32842143
3.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica
; 108(8): 2192-2204, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546453
4.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175021
5.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
6.
Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.
Clin Gastroenterol Hepatol
; 20(3): e508-e528, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857637
7.
Protein expression and purification of G-protein coupled receptor kinase 6 (GRK6), toward structure-based drug design and discovery for multiple myeloma.
Protein Expr Purif
; 185: 105890, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33971243
8.
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Blood
; 132(6): 587-597, 2018 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29884741
9.
Identification of PIKfyve kinase as a target in multiple myeloma.
Haematologica
; 105(6): 1641-1649, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582538
10.
Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.
Blood
; 129(8): 991-1007, 2017 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28028022
11.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
Blood
; 130(10): 1198-1204, 2017 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28684537
12.
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Lancet Oncol
; 19(7): 953-964, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866475
13.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med
; 372(2): 142-52, 2015 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25482145
14.
The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice.
Blood
; 127(13): 1676-86, 2016 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-26825710
15.
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Blood
; 128(9): 1226-33, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27458004
16.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Blood
; 128(9): 1174-80, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27439911
17.
Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
Ann Hematol
; 97(8): 1453-1462, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29623394
18.
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Br J Haematol
; 177(3): 404-413, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211560
19.
Multidisciplinary model to implement pharmacogenomics at the point of care.
Genet Med
; 19(4): 421-429, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27657685
20.
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Blood
; 126(11): 1294-301, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26157076